Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12612000900819
Ethics application status
Approved
Date submitted
17/08/2012
Date registered
24/08/2012
Date last updated
24/08/2012
Type of registration
Prospectively registered
Titles & IDs
Public title
Addressing the needs of osteoporosis prevention in postmenopausal women attending a tertiary hospital in Malaysia
Query!
Scientific title
Addressing the needs of osteoporosis prevention in postmenopausal women attending a tertiary hospital in Malaysia via osteoporosis screening conducted by pharmacist to identify undiagnosed osteoporosis cases.
Query!
Secondary ID [1]
281053
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Osteoporosis prevention in postmenopausal women
287194
0
Query!
Condition category
Condition code
Musculoskeletal
287523
287523
0
0
Query!
Osteoporosis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The interventional package:
At baseline:
a. One counselling session on the safe use of medications and lifestyle education.
(This will be an individual counselling session with a trained pharmacist which will take about 30 minutes)
b. Osteoporosis risk assessment using the tool Osteoporosis Screening Tool for Asians(OSTA).
(The osteoporosis risk of the patients will be assessed only at baseline by the pharmacist using the OSTA which utilizes a simple calculation using the age and weight of the patients. This will take about 5 minutes.)
c. Recommendation by pharmacist for Bone Mineral Density(BMD) scan as necessary.
d. Assessment of knowledge using the knowledge tool Osteoporosis Prevention Awareness Assessment Tool(OPAAT).
(OPAAT is a close ended questionaire that will be administered to the patients. This will take about 15 minutes.)
e. Recommendation by pharmacist for referral to the osteoporosis clinic as necessary.
First follow up phone (one month later):
a. Assessment of knowledge (OPAAT)
b. Assessment of satisfaction using the Satisfaction Questionaire for Osteoporosis Prevention(SQOP)
(SQOP is a close ended questionaire that will be administered to patient. This will take about 10 minutes)
Second follow up via phone(three months later):
To assess if patients attended the osteoporosis clinic
To assess if patients were started on osteoporosis medication
Query!
Intervention code [1]
285511
0
Early detection / Screening
Query!
Comparator / control treatment
Standard care refers to usual visit to the doctor with no routine osteoporosis screening services conducted
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
287766
0
Number of patients diagnosed with osteoporosis/osteopenia
(self report and countercheck with medical record data)
Query!
Assessment method [1]
287766
0
Query!
Timepoint [1]
287766
0
At 6 months after randomisation
Query!
Primary outcome [2]
287767
0
Number of patients sent for BMD scan
(self report and countercheck with medical record data)
Query!
Assessment method [2]
287767
0
Query!
Timepoint [2]
287767
0
At day 1 of randomisation
Query!
Primary outcome [3]
287768
0
Health economic benefit
(medical record data and statistical calculations)
Query!
Assessment method [3]
287768
0
Query!
Timepoint [3]
287768
0
At 6 months of randomisaion
Query!
Secondary outcome [1]
298804
0
Patient satisfaction (SQOP)
Query!
Assessment method [1]
298804
0
Query!
Timepoint [1]
298804
0
At 1 month after randomisation
Query!
Secondary outcome [2]
298805
0
Knowledge of osteoporosis (OPAAT)
Query!
Assessment method [2]
298805
0
Query!
Timepoint [2]
298805
0
At 1 month after randomisation
Query!
Secondary outcome [3]
298806
0
Reasons why the BMD scan was not ordered although recommended
(open ended questionnaire)
Query!
Assessment method [3]
298806
0
Query!
Timepoint [3]
298806
0
At 1 month after randomisation
Query!
Eligibility
Key inclusion criteria
All post menopausal women above 50 years of age and who are able to converse in English
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Women who were previously diagnosed with osteoporosis or refuse to participate in this study
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/08/2013
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
240
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
4490
0
Malaysia
Query!
State/province [1]
4490
0
Wilayah Persekutuan
Query!
Funding & Sponsors
Funding source category [1]
285837
0
Self funded/Unfunded
Query!
Name [1]
285837
0
Toh Li Shean
Query!
Address [1]
285837
0
103, Jalan Hujan Emas 5,
Overseas Union Garden,
58200 Kuala Lumpur,
Malaysia
Query!
Country [1]
285837
0
Malaysia
Query!
Primary sponsor type
University
Query!
Name
University of Nottingham
Query!
Address
School of Pharmacy, Faculty of Science, University of Nottingham Malaysia Campus, Jalan Broga, 43500 Semenyih, Selangor, Malaysia
Query!
Country
Malaysia
Query!
Secondary sponsor category [1]
284657
0
University
Query!
Name [1]
284657
0
University of Malaya
Query!
Address [1]
284657
0
Department of Primary Care Medicine, Faculty of Medicine Building, University of Malaya, 50603 Kuala Lumpur, MALAYSIA
Query!
Country [1]
284657
0
Malaysia
Query!
Secondary sponsor category [2]
284658
0
University
Query!
Name [2]
284658
0
University of Nottingham
Query!
Address [2]
284658
0
School of Pharmacy Building, University Park, University of Nottingham, Nottingham NG7 2RD, United Kingdom.
Query!
Country [2]
284658
0
United Kingdom
Query!
Ethics approval
Ethics application status
Approved
Query!
Summary
Brief summary
Osteoporosis is a preventable disease that causes bone loss increasing the risk for fractures. The World Health Organization provides that the worldwide projection of hip fractures cases due to osteoporosis will raise from 1.7 million in 1990 to 6.3 million by 2050 with a steep increase to be observed in developing countries.The needs of patients with osteoporosis may not be addressed as this disease is usually asymptomatic in its early stages. Hence, women who may have osteoporosis remained unidentified leading to possible unwanted fractures. Fractures are complications of untreated osteoporosis incurring a considerable amount of cost, and an increase in probability of morbidity and mortality. Therefore, prevention measures and screening which aid in early detection are the most effective and cost-effective ways to reduce the number of hospital admittance due to osteoporotic fractures thereby ensuring patient safety.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
34592
0
Query!
Address
34592
0
Query!
Country
34592
0
Query!
Phone
34592
0
Query!
Fax
34592
0
Query!
Email
34592
0
Query!
Contact person for public queries
Name
17839
0
TOH LI SHEAN
Query!
Address
17839
0
School of Pharmacy, Faculty of Science, University of Nottingham Malaysia Campus, Jalan Broga, 43500 Semenyih, Selangor, Malaysia.
Query!
Country
17839
0
Malaysia
Query!
Phone
17839
0
+60122846849
Query!
Fax
17839
0
Query!
Email
17839
0
[email protected]
Query!
Contact person for scientific queries
Name
8767
0
TOH LI SHEAN
Query!
Address
8767
0
School of Pharmacy, Faculty of Science, University of Nottingham Malaysia Campus, Jalan Broga, 43500 Semenyih, Selangor, Malaysia.
Query!
Country
8767
0
Malaysia
Query!
Phone
8767
0
+60122846849
Query!
Fax
8767
0
Query!
Email
8767
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF